Diagnostic Complexities and Challenging Therapeutics in Patients with Systemic Lupus Erythematosus and Thrombotic Microangiopathy (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #SA-PO0114; Pres time: Nov 8, 2025; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "First biopsy done 6 months before admission revealed class I lupus nephritis with TMA, and she was treated with rituximab, mycophenolate, voclosporin, corticosteroids, and hydroxychloroquine. Due to the patient's choice, given she had an episode of upper gastrointestinal bleeding, she decided to stop warfarin and was on apixaban...This case underscores the importance of high clinical suspicion, early complement testing, and potential consideration of complement inhibition (e.g., eculizumab). Genetic analysis may help confirm the diagnosis and guide therapy."
Clinical • Acute Kidney Injury • Anemia • Atypical Hemolytic Uremic Syndrome • Chronic Kidney Disease • Complement-mediated Rare Disorders • Gastroenterology • Genetic Disorders • Glomerulonephritis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • Thrombocytopenia
|
|
William Mauricio Paredes; Iman Waseem Chaudhry; Laura Ferreira Provenzano
|